AstraZeneca completes Ardea takeover

AstraZeneca said it had successfully completed its acquisition of California-based biotechnology company Ardea Biosciences.

The pharmaceutical giant said the $1.2bn deal would strengthen its late-stage pipeline with the addition of lesinurad, which is aimed at patients with gout.

Astra paid $32 per share, which at the time the takeover was announced was a 55% premium.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

At the time the deal completed the prices had equalised with Ardea shares changing hands at $31.96 at the close on Tuesday.

With the takeover complete, each outstanding share of Ardea common stock has been cancelled and converted into the right to receive $32.00, in cash, without interest.

Shares of Ardea have ceased trading on the NASDAQ.